Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 9Ovarian Neoplasms 8Breast Neoplasms 7Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytosis 1Solid Tumors 1Prostatic Neoplasms, Castration-Resistant 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasm Epithelial 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

olaparib 1cediranib 1bomedemstat 1atezolizumab 1Platinum 1Immunoglobulin G 1Etoposide 1Disulfides 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Extensive Stage Lung Small Cell Carcinoma × olaparib × Clear all
NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡